Gene Therapy Zolgensma Gains Approval In Spinal Muscular Atrophy Treatment; Novartis Stock Pops - Investor's Business Daily
- Gene Therapy Zolgensma Gains Approval In Spinal Muscular Atrophy Treatment; Novartis Stock Pops Investor's Business Daily
- At $2 million, priciest ever medicine treats fatal genetic disease NBC4i.com
- Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio Yahoo Finance
- At $2.1 million, new gene therapy is the most expensive drug ever MPR News
- FDA approves $2M medicine, most expensive ever WANE
- View full coverage on Google News